Biogen’s newly approved drug for Alzheimer’s disease could be the biggest seller ever, but it also might not work. Robert Cyran explains this duality and what it says about the U.S. healthcare spending spiral.
#Alzheimer #Biogen #FDA #News #Reuters
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: http://reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en